Search

Formoterol

[A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration … of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication.

Water

As a chemical compound, a water molecule contains one oxygen and two hydrogen atoms that are connected by covalent bonds. … Water is a liquid at standard ambient temperature and pressure, but it often co-exists on Earth with its solid state, ice; and gaseous state, steam (water vapor).

Colloidal oatmeal

It is available in topical products as a skin soothing agent. … Phenols are also contained in colloidal oatmeal, which possess antioxidant and anti-inflammatory activities, as well as UV-absorbing activity.

Alfuzosin

The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.

Pyrantel

A depolarizing neuromuscular-blocking agent causing longstanding nicotinic receptor activation, resulting in spastic paralysis of susceptible nematodes (worms). … Pyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900].

Anti-CD7 CAR T-cell therapy

Clarithromycin

Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.

Escitalopram

an inactive enantiomer. … Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].

STM-217

Valsartan

Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease … ARBs such as valsartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of